ABOS vs. BMEA, PRTK, OVID, ATHA, CHMA, ITOS, VALN, LXEO, KYTX, and ADPT
Should you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Biomea Fusion (BMEA), Paratek Pharmaceuticals (PRTK), Ovid Therapeutics (OVID), Athira Pharma (ATHA), Chiasma (CHMA), iTeos Therapeutics (ITOS), Valneva (VALN), Lexeo Therapeutics (LXEO), Kyverna Therapeutics (KYTX), and Adaptive Biotechnologies (ADPT). These companies are all part of the "medical" sector.
Biomea Fusion (NASDAQ:BMEA) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, community ranking, risk and analyst recommendations.
Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.
In the previous week, Biomea Fusion had 15 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 15 mentions for Biomea Fusion and 0 mentions for Acumen Pharmaceuticals. Biomea Fusion's average media sentiment score of 0.00 beat Acumen Pharmaceuticals' score of -0.38 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.
Biomea Fusion received 18 more outperform votes than Acumen Pharmaceuticals when rated by MarketBeat users. However, 65.52% of users gave Acumen Pharmaceuticals an outperform vote while only 61.67% of users gave Biomea Fusion an outperform vote.
Biomea Fusion's return on equity of -22.88% beat Acumen Pharmaceuticals' return on equity.
Biomea Fusion has a beta of -0.35, indicating that its share price is 135% less volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.15, indicating that its share price is 85% less volatile than the S&P 500.
Biomea Fusion currently has a consensus target price of $28.25, indicating a potential upside of 582.37%. Acumen Pharmaceuticals has a consensus target price of $12.00, indicating a potential upside of 358.02%. Given Acumen Pharmaceuticals' higher possible upside, research analysts clearly believe Biomea Fusion is more favorable than Acumen Pharmaceuticals.
96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 27.6% of Biomea Fusion shares are held by company insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Acumen Pharmaceuticals beats Biomea Fusion on 8 of the 15 factors compared between the two stocks.
Get Acumen Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acumen Pharmaceuticals Competitors List
Related Companies and Tools
